The AE-dependent level of ICAM-1 expression in the brain TME is also contrary to the low ICAM-1 expression reported in melanoma tumor models by Curley et al. (32), suggesting that the properties of the tumor TME need to be factored in when assessing the impact of MB-FUS in the brain TME and underscore the importance of controlled methods to promote desirable changes and compare findings across laboratories and clinical systems. This evidence concerns the gene ICAM1 and neoplasm.